Delving into the Latest Updates on Shengke Pharmaceutical (Jiangsu) Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Immune System Diseases

Hemic and Lymphatic Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	5
Immune System Diseases	2
Hemic and Lymphatic Diseases	2
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Small molecule drug	4
Unknown	2

Top 5 Target	Count

PCSK9(Proprotein convertase subtilisin kexin type 9)	1
NTRK(Neurotrophic tyrosine kinase receptor)	1
CDK4 x CDK6 x PIM3	1
CDK6 x CSF-1R x FLT3	1
CDK x TrkC	1

主要目的： 1. 评价 ETH-155008在复发性或难治性急性髓系白血病（AML）和非霍奇金淋巴瘤（NHL）患者的安全性和耐受性， 2. 确定ETH-155008的最大耐受剂量（MTD），以及II期推荐剂量（RP2D）。次要目的： 1. 评价 ETH-155008 在复发性或难治性AML和NHL患者中单次、多次口服给药后的药代动力学（PK）特征； 2. 评价 ETH-155008 的药效动力学（PD）特征； 3. 评价 ETH-155008 在复发性或难治性AML和NHL患者中的初步抗肿瘤疗效。 4. 评价对ETH-155008治疗反应的生物标志物，可能包括但不限于与有效/耐药相关的基因突变和表达特征。

[Translation]

Primary objectives: 1. To evaluate the safety and tolerability of ETH-155008 in patients with relapsed or refractory acute myeloid leukemia (AML) and non-Hodgkin's lymphoma (NHL); 2. To determine the maximum tolerated dose (MTD) of ETH-155008 and the recommended dose (RP2D) for Phase II. Secondary objectives: 1. To evaluate the pharmacokinetic (PK) characteristics of ETH-155008 in patients with relapsed or refractory AML and NHL after single and multiple oral administrations; 2. To evaluate the pharmacodynamic (PD) characteristics of ETH-155008; 3. To evaluate the preliminary anti-tumor efficacy of ETH-155008 in patients with relapsed or refractory AML and NHL. 4. To evaluate biomarkers of response to ETH-155008 treatment, which may include but are not limited to gene mutations and expression characteristics associated with efficacy/resistance.

Start Date27 Oct 2022

Sponsor / Collaborator

Shengke Pharmaceutical (Jiangsu) Co., Ltd.

NCT04840784 / TerminatedPhase 1

A Phase 1a/1b Dose Escalation and Dose Expansion, First-in-human, Open-Labeled Study of ETH-155008 in Subjects With Relapsed or Refractory B-cell NHL, CLL/SLL and AML

This Trial is a FIH, open-label, multicenter trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ETH-155008 in subjects with R/R B-cell NHL, CLL/SLL and AML who previously received standard treatment or are ineligible for standard treatment options.

Start Date29 Jun 2021

Sponsor / Collaborator

Shengke Pharmaceutical (Jiangsu) Co., Ltd.

100 Clinical Results associated with Shengke Pharmaceutical (Jiangsu) Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shengke Pharmaceutical (Jiangsu) Co., Ltd.

Login to view more data

100 Deals associated with Shengke Pharmaceutical (Jiangsu) Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shengke Pharmaceutical (Jiangsu) Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

3

1

Preclinical

IND Approval

1

Phase 1 Clinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

ETH-155008 ( CDK4 x CDK6 x PIM3 )	Non-Hodgkin Lymphoma More	Phase 1
ETH-155036 ( CDK6 x CSF-1R x FLT3 )	Relapsing acute myeloid leukemia More	IND Approval
ETH-201 ( PCSK9 )	Cardiovascular Diseases More	Preclinical
ETH-154 ( CDK x TrkC )	Squamous Cell Carcinoma of Head and Neck More	Discovery
ETH-168 ( NTRK )	Solid tumor More	Discovery